Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability

• Main Authors: Nikola Mantov (Author), Mathilde Zrounba (Author), Marion Brollo (Author), S Grassin-Delyle (Author), Matthieu Glorion (Author), Mélanie David (Author), Emmanuel Naline (Author), Philippe Devillier (Author), Hélène Salvator (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: The Janus kinase (JAK) 1/2 inhibitor ruxolitinib has been approved in an indication of myelofibrosis and is a candidate for the treatment of a number of inflammatory or autoimmune diseases. We assessed the effects of ruxolitinib on lipopolysaccharide (LPS)- and poly (I:C)-induced cytokin...